Filter your search
Vaccines Market ReportsX
Kalorama Information studies on the pharmaceutical vaccines industry cover the global market opportunity in full, with data on major competitors, market direction, and the pediatric and adult segments. Kalorama reports examine the global vaccines market by region, including the US, South America, EU, Japan, India, and China, as well as by type, including hepatitis, pneumococcal, cervical cancer, and influenza, among others. Market share of major vaccine companies is reported as well.
- $500.00 – $2,400.00The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. […]May 1, 2010$1,500.00 – $8,400.00The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who […]February 1, 2010$2,995.00 – $5,990.00With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are […]September 1, 2009$3,995.00 – $7,990.00The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions. This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used […]June 1, 2009$3,995.00 – $7,990.00It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products. There are several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are […]November 1, 2008$995.00 – $8,200.00Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information’s The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have […]April 1, 2008$3,995.00 – $7,990.00What are the trends that are fueling a new boom in vaccine production and sales? Why is an industry so commonly associated with children finding an increasing marketplace among adult populations? What makes this class of drugs likely to grow at a faster rate than other pharmaceutical products? These are among the questions answered in […]February 1, 2007$1,200.00 – $7,000.00Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, […]November 1, 2006$3,500.00 – $7,000.00This report covers pediatric and adult preventive vaccine products and provides an analysis of therapeutic vaccines for cancer treatment. In assessing the market for vaccine products, Kalorama Information provides sales data for the 2001-2003 historical years, the 2004 base year, and the 2001 through 2010 forecast years. Revenues are expressed in terms of manufacturers’ annual […]November 1, 2004$3,500.00 – $7,000.00The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more […]January 1, 2004